Avastin

Pia Baumann, CMO Medivir

Medivir – live from ESMO in Barcelona

Medivir has presented mature results from the ongoing Phase Ib/IIa study with fostrox in combination with Lenvima, confirming the potential...

Intervju
Video
Pia Baumann, CMO Medivir

Medivir's CMO: "Our new clinical data is very encouraging"

Medivir presents the first clinical results with fostrox...

Intervju
Medivir announces improved durable clinical benefit with fostrox

Medivir sees lasting clinical benefit with fostrox

Medivir, whose ongoing rights issue ends today, the 21st...
Medivir clears key hurdles ahead of phase IIb

Medivir checks off two steps ahead of Phase IIb

Medivir, which is currently in the process of issuing shares, has made progress in a short time...
Medivir aims for accelerated FDA approval through issuance

Medivir aims for accelerated FDA approval through issuance

Hepatocellular carcinoma is the most common form of primary...
Medivir's CEO: "We have attracted interest from the best investigators and hospitals to be part of the phase IIb study"

Medivir's CEO comments on the ongoing rights issue

Medivir is currently conducting a rights issue of up...

Intervju

Issue to bring market within reach for Xbrane Biopharma

Xbrane Biopharma is a biosimilars company whose lead candidate,...